Piper Sandler Reaffirms Overweight Rating for Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT)‘s stock had its “overweight” rating reiterated by equities research analysts at Piper Sandler in a report released on Monday,Benzinga reports. They currently have a $115.00 price objective on the healthcare product maker’s stock. Piper Sandler’s price target indicates a potential upside of 30.38% from the stock’s current price.

A number of other brokerages also recently weighed in on ABT. Daiwa Securities Group downgraded Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price target for the company. in a report on Wednesday, April 22nd. Raymond James Financial cut their target price on Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Argus decreased their target price on Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating for the company in a research note on Tuesday, April 21st. TD Cowen dropped their price target on Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Finally, Mizuho cut their price target on Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating on the stock in a report on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $118.30.

Abbott Laboratories Trading Down 0.2%

Shares of NYSE ABT traded down $0.21 during midday trading on Monday, reaching $88.20. The stock had a trading volume of 4,490,125 shares, compared to its average volume of 12,140,896. The company’s 50 day moving average price is $90.08 and its 200 day moving average price is $106.45. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $139.06. The firm has a market cap of $153.63 billion, a price-to-earnings ratio of 24.69, a price-to-earnings-growth ratio of 1.52 and a beta of 0.63.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.01. The company had revenue of $11.16 billion during the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. Abbott Laboratories’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period in the prior year, the company posted $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, sell-side analysts expect that Abbott Laboratories will post 5.48 EPS for the current year.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau acquired 2,200 shares of Abbott Laboratories stock in a transaction dated Thursday, April 23rd. The stock was purchased at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the acquisition, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at $201,300. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Daniel J. Starks bought 10,000 shares of the stock in a transaction that occurred on Monday, April 27th. The stock was acquired at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the acquisition, the director directly owned 6,751,103 shares in the company, valued at $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders own 0.46% of the company’s stock.

Institutional Trading of Abbott Laboratories

Several institutional investors and hedge funds have recently modified their holdings of ABT. Southern Financial Group LLC lifted its holdings in Abbott Laboratories by 14.3% during the first quarter. Southern Financial Group LLC now owns 2,195 shares of the healthcare product maker’s stock worth $225,000 after acquiring an additional 274 shares during the period. Lombard Odier Asset Management Europe Ltd grew its stake in Abbott Laboratories by 3.1% in the 1st quarter. Lombard Odier Asset Management Europe Ltd now owns 18,304 shares of the healthcare product maker’s stock valued at $1,879,000 after purchasing an additional 554 shares during the period. US Asset Management LLC increased its position in shares of Abbott Laboratories by 27.4% during the 1st quarter. US Asset Management LLC now owns 3,682 shares of the healthcare product maker’s stock valued at $378,000 after purchasing an additional 793 shares during the last quarter. Rathbones Group PLC raised its stake in shares of Abbott Laboratories by 2.5% during the 1st quarter. Rathbones Group PLC now owns 3,194,265 shares of the healthcare product maker’s stock worth $327,955,000 after purchasing an additional 77,879 shares during the period. Finally, Wealthquest Corp boosted its holdings in shares of Abbott Laboratories by 10.0% in the 1st quarter. Wealthquest Corp now owns 7,835 shares of the healthcare product maker’s stock worth $804,000 after buying an additional 713 shares during the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.